![]() “Our facility’s location, next to Los Angeles International Airport, one of the largest and busiest airports in North America, is ideal for expediting the shipment of CAR T therapies.”Īs for the manufacturing process, Moore said the El Segundo site will have the capacity to produce up to 4,000-5,000 patient therapies per year using semi-automated equipment source from multiple suppliers. Time is critical for patients who receive CAR T therapies, and this was a factor in the location of the new facility. “The entire vein-to-vein process takes about 14 days, one of the fastest in the industry.” The modified cells are then frozen and shipped back to the patient, Moore continued, where they are re-infused into the patient. “ In a six to eight day process utilising Kite’s proprietary genetic engineering technology, the cells are re-engineered to seek and selectively destroy cancer cells while leaving normal cells unharmed.” “ therapies involve a process of extracting cells from a cancer patient and air shipping them to our El Segundo facility,” he told. The product is intended to treat chemorefractory diffuse large B-cell lymphoma (DLBCL) and is an autologous chimeric antigen receptor (CAR) T-cell therapy, meaning it is made using a patient’s own modified cells, as Kite’s EVP of technical operations Timothy Moore explained. ![]() The 43,500 sq ft plant in El Segundo, California officially opened its doors last week, ahead of the US approval and launch of Kite Pharma’s lead candidate, KTE-C19, anticipated by the firm next year.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |